To read the full story, subscribe or sign in.

United Therapeutics discontinues development of esuberaprost based on BEAT results in PAH

April 8, 2019

No Comments

BioWorld Science Cardiovascular

Today's news in brief

BioWorld

BioWorld briefs for Dec. 7, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 7, 2023.

‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

BioWorld

For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...

Off-target immune response from modified mRNA impacts future development

BioWorld

The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...

Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

BioWorld

Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...

Upgrade your daily dose of biopharma and medtech news

United Therapeutics discontinues development of esuberaprost based on BEAT results in PAH